SCHEMBL15538262

SCHEMBL15538262

Fc1cc(Br)ccc1OCC1CCN(CC2(C(F)(F)F)CCC2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KDM1A O60341 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
RET P07949 3/20 0.37
GPR119 Q8TDV5 2/20 0.37
EGFR P00533 5/20 0.37
KDR P35968 5/20 0.37
FGFR1 P11362 4/20 0.37
FLT1 P17948 4/20 0.37
FLT4 P35916 4/20 0.37
PDGFRB P09619 2/20 0.37
TEK Q02763 2/20 0.37
BMPR1B O00238 1/20 0.37
PLK4 O00444 1/20 0.37
CIT O14578 1/20 0.37
GAK O14976 1/20 0.37
EPHB6 O15197 1/20 0.37
RIPK2 O43353 1/20 0.37
ROCK2 O75116 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16777101 0.84 HRH3 (0.36) GPR119HRH3
SCHEMBL15538403 0.83 SIGMAR1 (0.41)
SCHEMBL15537544 0.81 PARP10 (0.38)
SCHEMBL15539778 0.81 CHRM2 (0.40) CHRM2CHRM1CHRM3KCNH2
SCHEMBL15537653 0.80 GPR119 (0.46) SMN1; SMN2KDM1AGPR119
SCHEMBL16777129 0.79 GPR119 (0.38) GPR119CHRM2CHRM1CHRM3DRD3
SCHEMBL15538591 0.79 RET (0.42) MAPTSMN1; SMN2KDM1ARETEGFR
SCHEMBL16777106 0.79 WNT1 (0.40) GPR119CHRM2CHRM1CHRM3KCNH2
SCHEMBL20053534 0.79 KCNH2 (0.39) GPR119CHRM2CHRM1CHRM3KCNH2
SCHEMBL15538331 0.78 SIGMAR1 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2858986-B1 PIPERIDINE DERIVATIVES AS GPR119 AGONISTS CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2019-10-30 EP disclosed
US-9944600-B2 Piperidine derivatives for GPR119 agonist CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2018-04-17 US disclosed
US-20150166480-A1 PIPERIDINE DERIVATIVES FOR GPR119 AGONIST CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2015-06-18 US disclosed
EP-2858986-A1 PIPERIDINE DERIVATIVES FOR GPR119 AGONIST Chong Kun Dang Pharmaceutical Corp. (KR) 2015-04-15 EP disclosed
WO-2013187646-A1 PIPERIDINE DERIVATIVES FOR GPR119 AGONIST CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2013-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166480-A1 PIPERIDINE DERIVATIVES FOR GPR119 AGONIST GPR119, FFAR2, GPR84 MAPT 4394/4885SMN1; SMN2 3245/4885KDM1A 1922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.